Posted by Michael Wonder on 23 Dec 2025
Invivyd earns fast track designation for VYD2311, a vaccine alternative antibody to prevent COVID
23 December 2025 - Invivyd today announced that the US FDA has granted fast track designation for VYD2311, an investigational vaccine alternative monoclonal antibody candidate for the prevention of COVID.
VYD2311 is a novel monoclonal antibody candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options.
